APTX

Aptinyx Inc. [APTX] Stock Forecast

Q: What is Aptinyx Inc. stock symbol ?

Aptinyx Inc. is a US stock, located in Evanston of Il and trading under the symbol APTX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

APTX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has been increasing for the past 3 quarters (Quarter statements)

Earnings are expected to fall -100% next year

Does not have any significance market cap ($10.23M)

Top 10 Correlated ETFs

APTX

Top 10 Correlated Stocks

APTX

In the News

01:00 26 Mar 2023 APTX

COYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar

COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.

08:36 26 Mar 2023 APTX

Why Is Aptinyx (APTX) Stock Down 64% Today?

Aptinyx (NASDAQ: APTX ) stock is taking a beating on Tuesday after the company revealed results from a Phase 2 clinical trial. The bad news here is that this clinical trial failed to meet its primary endpoint.

07:47 26 Mar 2023 APTX

Aptinyx to Present at the SVB Securities Global Biopharma Conference

EVANSTON, Ill.--( BUSINESS WIRE )--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m. ET.

09:46 26 Mar 2023 APTX

Aptinyx Inc. (APTX) CEO Andy Kidd on Q3 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & IR Andy Kidd - President and CEO Ashish Khanna - CFO and CBO Kathryn King - SVP, Clinical and CMC Operations Conference Call Participants Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Third Quarter 2022 Financial Results Conference Call.

07:45 26 Mar 2023 APTX

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

EVANSTON, Ill.

12:48 26 Mar 2023 APTX

Aptinyx's (APTX) Mid-Stage Fibromyalgia Study Fails to Meet Goal

Aptinyx (APTX) reports disappointing data from a mid-stage study assessing NYX-2925 for the treatment of fibromyalgia. Stocks decline

07:13 26 Mar 2023 APTX

Aptinyx Inc. (APTX) CEO Andy Kidd on Q2 2022 Results - Earnings Call Transcript

Aptinyx Inc. (NASDAQ:APTX ) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Patrick Flavin - Senior Manager, Corporate Development & Investor Relations Andy Kidd - President & Chief Executive Officer Ashish Khanna - Chief Financial Officer & Chief Business Officer Kathryn King - Senior Vice President, Clinical & CMC Operations Conference Call Participants Ritu Baral - Cowen Evan Hua - BMO Capital Markets Myles Minter - William Blair Boobalan Pachaiyappan - H.C. Wainwright Operator Good afternoon and welcome to the Aptinyx Second Quarter 2022 Financial Results Conference Call.

07:47 26 Mar 2023 APTX

Aptinyx to Report Second Quarter 2022 Financial Results on Thursday, August 4, 2022

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2022 at 5:00 p.m. ET to report second quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial (888) 660-6390 (domestic) or (929) 203-1902

07:37 26 Mar 2023 APTX

Aptinyx to Participate in H.C. Wainwright Global Investment Conference

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present at the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, beginning at 7:00 AM ET on Tuesday, May 24, 2022. A webcast recording of the presentat

12:50 26 Mar 2023 APTX

Aptinyx, Inc. (APTX) CEO Andy Kidd on Q1 2022 Results - Earnings Call Transcript

Aptinyx, Inc. (NASDAQ:APTX ) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants Pat Flavin - IR Andy Kidd - CEO Ashish Khanna - CFO Kathryn King - SVP of Clinical and CMC operations Harald Murck - VP of Medical and Clinical Affairs Conference Call Participants Ritu Baral - Cowen Charles Duncan - Cantor Fitzgerald Myles Minter - William Blair Operator Good afternoon, and welcome to the Aptinyx First Quarter 2022 Financial Results Conference Call. [Operator Instructions] Please be advised the call is being recorded at the company's request.

APTX Financial details

Company Rating

Neutral

Market Cap

10.23M

Income

-37.49M

Revenue

Book val./share

0.72

Cash/share

0.98

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

24 Mar 2023

P/E

-0.27

Forward P/E

PEG

0.15

P/S

P/B

0.21

P/C

0.15

P/FCF

-0.12

Quick Ratio

24.72

Current Ratio

27.45

Debt / Equity

0.56

LT Debt / Equity

EPS (TTM)

-0.84

EPS next Y

EPS next Q

EPS this Y

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

-27.41%

Revenue Q/Q

EPS Q/Q

SMA20

-74.14%

SMA50

-61.54%

SMA100

-44.44%

Inst Own

42.98%

Inst Trans

-2.95%

ROA

-49%

ROE

-53%

ROC

-0.96%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

67.72M

Shs Float

38.42M

Target Price

52W Range

0.13-2.87

52W High

52W Low

RSI

34.92

Rel Volume

12.41

Avg Volume

2.37M

Volume

29.41M

Perf Week

8.32%

Perf Month

-76.62%

Perf Quarter

-58.98%

Perf Half Y

-66.44%

Beta

1.38858

Volatility

0.01%, 0.21%

Prev Close

-15.36%

Price

0.151

Change

2.03%

APTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2021-12-31

Metric	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31
Revenue per share	0.29	0.33	0.11	0.03	0.02
Net income per share	-1.91	-2.64	-1.71	-1.02	0
Operating cash flow per share	-1.94	-2.35	-1.55	-0.87	-1.3
Free cash flow per share	-2.04	-2.37	-1.55	-0.87	-1.3
Cash per share	5.47	7.46	2.95	2.89	2.17
Book value per share	-2.36	7.39	3.02	2.99	1.94
Tangible book value per share	-2.36	7.39	3.02	2.99	1.94
Share holders equity per share	-2.36	7.39	3.02	2.99	1.94
Interest debt per share	0	0	0	0	0
Market cap	339.99M	334.09M	114.76M	169.08M	130.47M
Enterprise value	247.85M	183.45M	15.91M	28.05M	24.35M
P/E ratio	-10.6	-6.27	-2	-3.38	0
Price to sales ratio	68.52	50.82	31.28	108.11	130.47
POCF ratio	-10.39	-7.04	-2.2	-3.99	-2.06
PFCF ratio	-9.91	-6.98	-2.2	-3.97	-2.06
P/B Ratio	-8.56	2.24	1.13	1.16	1.38
PTB ratio	-8.56	2.24	1.13	1.16	1.38
EV to sales	49.95	27.91	4.34	17.93	24.35
Enterprise value over EBITDA	-7.83	-3.47	-0.28	-0.57	-0.33
EV to operating cash flow	-7.57	-3.87	-0.31	-0.66	-0.38
EV to free cash flow	-7.22	-3.83	-0.31	-0.66	-0.38
Earnings yield	-0.09	-0.16	-0.5	-0.3	0
Free cash flow yield	-0.1	-0.14	-0.45	-0.25	-0.49
Debt to equity	-3.45	0.04	0.05	0.03	0.21
Debt to assets	1.41	0.04	0.05	0.03	0.18
Net debt to EBITDA	2.91	2.85	1.74	2.84	1.43
Current ratio	21.74	26.04	21.47	32.64	20.18
Interest coverage	0	0	0	0	0
Income quality	1.02	0.89	0.91	0.85	0
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	1.12	1.93	5.17	12.46	0
Research and developement to revenue	6.38	7.42	12.08	20.99	55.44
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	0.01	0	0.01	0
Capex to revenue	-0.32	-0.06	-0.01	-0.14	0.12
Capex to depreciation	-3.89	-0.89	-0.09	-0.51	0.23
Stock based compensation to revenue	0.18	0.5	2.46	6.38	9.72
Graham number	10.06	20.95	10.78	8.3	0
ROIC	0.36	0.37	0.64	0.38	0
Return on tangible assets	-0.33	-0.34	-0.54	-0.33	0
Graham Net	-2.63	7.17	2.8	2.79	1.76
Working capital	90.66M	147.37M	100.21M	145.02M	109.06M
Tangible asset value	-39.72M	149.31M	101.31M	145.91M	94.76M
Net current asset value	-42.01M	146.95M	99.94M	144.91M	94.57M
Invested capital	0	0	0	0	0
Average receivables	712.5K	757.5K	511K	350.5K	128.5K
Average payables	1.57M	1.71M	1.72M	1.38M	915.5K
Average inventory	0	0	0	0	0
Days sales outstanding	68.92	32.09	44.17	59.98	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	5.3	11.37	8.26	6.09	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	0.81	-0.36	-0.57	-0.34	0
Capex per share	-0.09	-0.02	0	0	0

Quarterly Fundamentals Overview

Last date of statement is 2022-09-30 for Q3

Metric	2021-09-30	2021-12-31	2022-03-31	2022-06-30	2022-09-30
Revenue per share	0	0	0	0	0
Net income per share	-0.31	0	-0.29	-0.26	0
Operating cash flow per share	-0.27	-0.28	-0.24	-0.22	-0.51
Free cash flow per share	-0.27	-0.28	-0.24	-0.22	-0.51
Cash per share	1.85	1.57	1.48	1.26	0.98
Book value per share	1.65	1.4	1.14	0.92	0.72
Tangible book value per share	1.65	1.4	1.14	0.92	0.72
Share holders equity per share	1.65	1.4	1.14	0.92	0.72
Interest debt per share	0.21	0	0.37	0.37	0.01
Market cap	158.46M	180.8M	153.72M	37.78M	24.93M
Enterprise value	47.2M	74.68M	77.85M	-22.99M	-41.66M
P/E ratio	-1.87	0	-1.94	-0.53	0
Price to sales ratio	0	0	0	0	0
POCF ratio	-8.51	-9.49	-9.65	-2.56	-0.72
PFCF ratio	-8.51	-9.55	-9.65	-2.56	-0.72
P/B Ratio	1.41	1.91	1.98	0.61	0.51
PTB ratio	1.41	1.91	1.98	0.61	0.51
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.23	-3.9	-4.03	1.36	2.86
EV to operating cash flow	-2.54	-3.92	-4.89	1.56	1.21
EV to free cash flow	-2.54	-3.94	-4.89	1.56	1.21
Earnings yield	-0.13	0	-0.13	-0.47	0
Free cash flow yield	-0.12	-0.1	-0.1	-0.39	-1.39
Debt to equity	0.18	0.21	0.38	0.49	0.56
Debt to assets	0.16	0.18	0.27	0.33	0.36
Net debt to EBITDA	5.25	5.55	3.93	3.6	4.56
Current ratio	21.07	20.18	22.49	16.22	27.45
Interest coverage	0	0	-40.63	-22.6	-17.16
Income quality	0.88	0	0.8	0.84	0.98
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0	-0.01	0	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	0	3.18	0	0	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	3.42	0	2.75	2.32	0
ROIC	0.18	0	0.2	0.21	0
Return on tangible assets	-0.16	0	-0.19	-0.19	0
Graham Net	1.55	1.27	1.05	0.81	0.58
Working capital	126.12M	109.06M	101.79M	86.46M	71.26M
Tangible asset value	112.04M	94.76M	77.49M	62.1M	48.79M
Net current asset value	111.8M	94.57M	77.36M	61.93M	46.54M
Invested capital	0.13	0	0.31	0.39	0
Average receivables	0	0	0	0	0
Average payables	1.78M	1.87M	1.19M	1.93M	1.29M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.19	0	-0.26	-0.28	0
Capex per share	0	0	0	0	0

APTX Frequently Asked Questions

What is Aptinyx Inc. stock symbol ?

Aptinyx Inc. is a US stock , located in Evanston of Il and trading under the symbol APTX

Is Aptinyx Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $1. The lowest prediction is $1 and the highest is $1

What is APTX stock prediction ?

What is Aptinyx Inc. stock quote today ?

Aptinyx Inc. stock price is $0.151 today.

Is Aptinyx Inc. stock public?

Yes, Aptinyx Inc. is a publicly traded company.

Something similar

Top by Market Cap

TL0.DE

BRYN.DE

AAPL

Company Profile

Volume Average 2.37M
Market Capitalization 10.23M
Employee 40
CEO Dr. Andrew D. Kidd B.M. B.Ch., M.D.
Headquarters Evanston,IL,US
IPO Date 2018-06-21
Website https://www.aptinyx.com

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.